Ohio Administrative Code
Title 5160 - Ohio Department of Medicaid
Chapter 5160-4 - Physician Services
Section 5160-4-12 - Immunizations, injections and infusions (including trigger - point injections), skin substitutes, and provider-administered pharmaceuticals
Universal Citation: OH Admin Code 5160-4-12
Current through all regulations passed and filed through September 16, 2024
(A) General provisions.
(1) A
"not otherwise specified," "unlisted," or "miscellaneous" procedure code should
be reported on a claim only if no procedure code is available that identifies
the particular service or item provided.
(2)
No separate payment is made for an immunization, injection, infusion, vaccine,
toxoid, or provider-administered pharmaceutical as a medical service if it is
provided in a hospital setting (inpatient hospital, outpatient hospital, or
hospital emergency department).
(3) A
provider-administered pharmaceutical reported on a claim submitted in
accordance with Chapter 5160-9 of the Administrative Code is regarded as a
pharmacy service rather than a
professional medical service, and payment of the
claim is governed by the provisions of that chapter. For example, a vaccine,
toxoid, or other provider-administered pharmaceutical prescribed for a resident
of a long-term care facility (LTCF) and subsequently administered by a LTCF
staff member is a pharmacy service.
(4) Payment for an
immunization, injection, or infusion includes related supplies (e.g., alcohol wipes,
needles, syringes, and tubing).
(B) Coverage of immunizations. An immunization has two components: the administration of the vaccine or toxoid and the vaccine or toxoid itself.
(1) Payment
for administration may take one of two forms:
(a) Payment for the most appropriate
administration procedure; or
(b)
Payment for the least complex evaluation and management service rendered to an
established patient.
(2)
Separate payment may be made for the vaccine or toxoid. No payment, however,
will be made for vaccines that can be obtained at no cost through the federal
vaccines for children (VFC) program, which is administered by the Ohio
department of health (ODH).
(3)
Limitations apply to certain vaccines.
(a)
Regardless of the formulation, payment for hepatitis B vaccine (HBV)
administered to individuals younger than nineteen years of age may be made only
under the VFC program. Different procedure codes
are reported
on claims to distinguish HBV administered to individuals younger than nineteen
from HBV administered to individuals nineteen or
older .
(b) Vaccines for the human papilloma virus
(HPV) are covered in accordance with the schedule regarding the appropriate
periodicity, dosage, and contraindications applicable to vaccines established
by the advisory committee on immunization practices of the centers for disease
control and prevention,
available from
http://www.cdc.gov.
(C) Coverage of therapeutic, prophylactic, or diagnostic injections or infusions (excluding chemotherapy and other complex procedures).
(1) An injection or infusion has two
components: the administration of a fluid medium and, except in the case of
hydration, the pharmaceutical itself. No separate payment is made for the
administration service if an injection or infusion is given during the course
of an office visit or in conjunction with another medical service that includes
an evaluation and management element.
(2) Payment may be made for an injection or
infusion or a provider-administered pharmaceutical only if at least one of the
following criteria is met:
(a) Its use for a
particular indication has been approved by the U.S. food and drug
administration; or
(b) According to
accepted standards of medical practice, it is a specific or effective treatment
for the particular condition for which it is given.
(3) No separate payment is made for an
injection or infusion or a provider-administered pharmaceutical that meets
either of the following criteria:
(a) The
frequency or duration of its administration exceeds accepted standards of
medical practice for the particular condition; or
(b) It is provided for or in association with
non-covered medicaid services, which are defined in rule
5160-1-61 of the Administrative
Code.
(4) Immune globulin
is covered when it is used to provide passive immunity to an individual who is
immunosuppressed; has an acquired or congenital immunodeficiency; is at risk of
Rh-isoimmunization; or is in immediate danger of
contracting a communicable disease through direct contact with blood, saliva,
or other body fluids through an open wound, bite, puncture, or mucous
membrane.
(5) Epoetin alfa (EPO)
for the treatment of anemia, either associated with or not related to chronic
renal failure, is covered as a medical service when a provider incurs the cost
of the drug and the service is provided in a
dialysis
center or office setting.
(6)
Certain procedure codes represent a specific number of dosage units. On a
claim, the fewest number of procedure codes
are to be
reported together to represent the administered dosage.
(D) Coverage of trigger-point injections.
(1) A trigger point is a hyperexcitable area
of the body, where the application of a stimulus will provoke pain to a greater
degree than in the surrounding area. The purpose of a trigger-point injection
is to treat not only the symptom but also the cause through the injection of a
single substance (e.g., a local anesthetic) or a mixture of substances (e.g., a
corticosteroid with a local anesthetic) directly into the affected body part in
order to alleviate inflammation and pain. Payment may be made for a
trigger-point injection only if the following criteria are met:
(a) The patient
has a
diagnosis for which the trigger-point injection is an appropriate treatment;
and
(b) The following information
is
documented in the patient's medical record:
(i) A proper evaluation including a patient
history and physical examination leading to diagnosis of the trigger
point;
(ii) The reason or reasons
for selecting this therapeutic option;
(iii) The affected muscle or
muscles;
(iv) The muscle or muscles
injected and the number of injections;
(v) The frequency of injections
required;
(vi) The name of the
medication used in the injection;
(vii) The results of any prior treatment;
and
(viii) Corroborating evidence
that the injection is medically necessary.
(2) A trigger-point injection is normally
considered to be a stand-alone service. No additional payment will be made for
an office visit on the same date of service unless there is an indication on
the claim (e.g., in the form of a modifier appended to the evaluation and
management procedure code) that a separate evaluation and management service
was performed.
(3) Certain
trigger-point injection procedure codes specify the number of injection sites.
For these codes, the unit of service is different from the number of injections
given. Payment may be made for one unit of service of the appropriate procedure
code reported on a claim for service rendered to a particular patient on a
particular date.
(4) Trigger-point
injections should be repeated only if doing so is reasonable and medically
necessary. For trigger-point injections of a local anesthetic or a steroid,
payment will be made for no more than eight dates of service per calendar year
per patient.
(E) Coverage of skin substitutes.
(1) Skin substitutes may
be used on burns or ulcers when grafting with actual skin is not an appropriate
option. Skin substitutes are expected to function as a permanent replacement
for lost or damaged skin. They may be used for temporary wound coverage or
wound closure as appropriate and medically necessary. Payment may be made for a
skin substitute if a practitioner determines that the skin substitute will be
of benefit for the particular type of wound.
(a) When a skin substitute is applied in an
office setting, payment may be made to a practitioner for both the skin
substitute and an appropriate skin application procedure.
(b) When a skin substitute is applied in a
hospital setting (inpatient hospital, outpatient hospital, or hospital
emergency department), payment may be made to a practitioner only for the skin
application procedure. Payment for the skin substitute is included in the
hospital's facility payment.
(c)
When a skin substitute is applied in a long-term care facility (LTCF), payment
may be made to a practitioner for the skin application procedure. Payment for
the skin substitute may be made to the practitioner only if the practitioner
supplies the skin substitute; otherwise, payment for the skin substitute is
included in the LTCF's facility payment.
(2) The results of treatment
are to
be documented in the individual's medical record. Payment will not be made for
additional applications or re-applications if the wound volume has not
decreased by at least fifty per cent after three separate treatments over
twelve weeks.
(F) Payment.
(1) On the
department's web site, http://medicaid.ohio.gov, is a list of
vaccines, toxoids, skin substitutes, and other provider-administered
pharmaceuticals each of which is covered by medicaid either as a medical
service or as a VFC-designated vaccine. Payment for a covered non-VFC vaccine,
toxoid, skin substitute, or other provider-administered pharmaceutical is the
lesser of the provider's submitted charge or the first applicable item
from the following ordered list:
(a) An amount specified
in or determined in accordance with the Administrative Code;
(b)
The state maximum allowable cost (SMAC), which is defined in rule
5160-9-05 of the Administrative
Code;
(c) The payment limit
shown in the current medicare part B drug pricing file, which is available at
http://www.cms.gov;
(d)
One hundred seven per cent of the wholesale acquisition cost (WAC);
or
(e) Eighty-five and
six-tenths per cent of the average wholesale price (AWP).
(2)
Payment for any other covered
administration service or evaluation and management service
listed in appendix DD to rule
5160-1-60 of the Administrative
Code is made in accordance with that
rule.
Disclaimer: These regulations may not be the most recent version. Ohio may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.